Opinion statement
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an incidence of about 1:2500 to 1:3000. It is caused by a germline inactivating mutation of the NF1 gene on chromosome 17. Patients with NF1 are at increased risk of developing a variety of tumors of the peripheral and central nervous system, including neurofibromas, plexiform neurofibromas, malignant peripheral nerve sheath tumors, and low-grade gliomas of the optic nerves and other cerebral structures. Rarely, they develop high-grade gliomas. Although they are rare, these hereditary tumor syndromes involving the nervous system must be recognized in patients and their families, as early diagnosis may alter management and ultimately improve outcome. Additional insight into the molecular mechanisms causing these syndromes and their relationship with the clinical features will allow the development and implementation of screening and prevention strategies for these diseases.
Management of these lesions is difficult and requires specific skills and the collaborative work of neurosurgeons, radiation therapists, neurologists, and oncologists. Ideally, patients should be managed in comprehensive centers with specific expertise in the management of patients with NF1. This review describes current and developing therapies for managing the neuro-oncologic manifestations of NF1.
Similar content being viewed by others
References and Recommended Reading
Walker L, Thompson D, Easton D, et al.: A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006, 95:233–238.
Gutmann DH: The neurofibromatoses: when less is more. Hum Mol Genet 2001, 10:747–755.
Williams VC, Lucas J, Babcock MA, et al.: Neurofibromatosis type 1 revisited. Pediatrics 2009, 123:124–133.
Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988, 45:575–578.
Ferner RE, Huson SM, Thomas N, et al.: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007, 44:81–88.
Packer RJ, Gutmann DH, Rubenstein A, et al.: Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002, 58:1461–1470.
Matsumine A, Kusuzaki K, Nakamura T, et al.: Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 2008 Dec 20 (Epub ahead of print).
Woodruff JM, Chernik NL, Smith MC, et al.: Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant “Triton” tumors). Cancer 1973, 32:426–439.
Viskochil DH: It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. J Clin Invest 2003, 112:1791–1793.
Friedrich RE, Schmelzle R, Hartmann M, Mautner VF: Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports. J Craniomaxillofac Surg 2005, 33:55–60.
Widemann BC, Salzer WL, Arceci RJ, et al.: Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006, 24:507–516.
Babovic-Vuksanovic D, Ballman K, Michels V, et al.: Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology 2006, 67:1860–1862.
Evans DG, Baser ME, McGaughran J, et al.: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311–314.
King AA, Debaun MR, Riccardi VM, Gutmann DH: Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000, 93:388–392.
Fisher MJ, Basu S, Dombi E, et al.: The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol 2008, 87:165–171.
Ferner RE, Golding JF, Smith M, et al.: [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008, 19:390–394.
Brenner W, Friedrich RE, Gawad KA, et al.: Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 2006, 33:428–432.
Gachiani J, Kim D, Nelson A, Kline D: Surgical management of malignant peripheral nerve sheath tumors. Neurosurg Focus 2007, 22:E13.
Carli M, Ferrari A, Mattke A, et al.: Pediatric malignant peripheral nerve sheath tumor: the Italian and German Soft Tissue Sarcoma Cooperative Group. J Clin Oncol 2005, 23:8422–8430.
Tabone-Eglinger S, Bahleda R, Côté JF, et al.: Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 2008:849156.
Lewis RA, Gerson LP, Axelson KA, et al.: von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984, 91:929–935.
Jahraus CD, Tarbell NJ: Optic pathway gliomas. Pediatr Blood Cancer 2006, 46:586–596.
King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003, 122:95–99.
Listernick R, Ferner RE, Liu GT, Gutmann DH: Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007, 61:189–198.
Astrup J: Natural history and clinical management of optic pathway glioma. Br J Neurosurg 2003, 17:327–335.
Packer RJ, Ater J, Allen J, et al.: Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997, 86:747–754.
Jenkin D, Angyalfi S, Becker L, et al.: Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 1993, 25:215–225.
Singhal S, Birch JM, Kerr B, et al.: Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child 2002, 87:65–70.
Packer RJ, Jakacki R, Horn M, et al.: Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009, 52:791–795.
Leonard JR, Perry A, Rubin JB, et al.: The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 2006, 67:1509–1512.
Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hottinger, A.F., Khakoo, Y. Neuro-oncology of neurofibromatosis type 1. Curr Treat Options Neurol 11, 306–314 (2009). https://doi.org/10.1007/s11940-009-0034-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11940-009-0034-4